Bhi Skin Tablet
FDA Label NDC 62795-1016

Full FDA labeling including Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Medinatura Inc for the product Bhi Skin (NDC 62795-1016). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding active ingredients, inactive ingredients, purpose, uses, directions, warnings section, keep out of reach of children, bhi skin tablet, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Active Ingredients

Each tablet contains: *Berberis vulgaris 6X, Graphites 10X, Hydrofluoricum acidum 10X, *Lycopodium clavatum 12X, *Petroleum 10X, *Rhus toxicodendron 8X, *Sepia 10X, *Sulphur 12X 37.5 mg each.

*Natural Ingredients

Inactive Ingredients

Lactose and Magnesium stearate

Purpose

Eczema Relief Tablets

Relieves:

• Rough Scaly Skin

• Itching Skin

• Redness

Uses

For the temporary relief of minor eczema symptoms: rough scaly skin, itching skin, redness

Directions

At first sign of symptoms:Adults and children 4 years and older: 1 tablet every 1/2 to 1 hour until symptoms lessen, then continue with standard dosage. Do not exceed 12 tablets in 24 hours.

Standard dosage: Adults and children 4 years and older: 3 tablets per day, taking 1 tablet every 4 to 6 hours. For children under 4, consult your health professional.

Allow tablets to dissolve completely in the mouth, do not swallow.

Warnings Section

If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. If symptoms persist or worsen, a health professional should be consulted. Do not use if known sensitivity to BHI Skin or any of its ingredients exists.

Keep Out Of Reach Of Children

Keep out of reach of children.

* Please review the disclaimer below.